Press "Enter" to skip to content

Novo Nordisk and Gilead team up to test fatty liver disease treatment

The clinical trial will be a study combining Novo Nordisk’s semaglutide drug and Gilead’s cilofexor and firsocostat for treatment of patients with Nonalcoholic steatohepatitis (NASH), Novo Nordisk, best known for its diabetes drugs, said on Friday.

Original source:

Also Read:   Rajkot : Pharmacists unite against online rivals